Updated survival results from a randomized, dose-ranging phase II study of nivolumab (NIVO) in metastatic renal cell carcinoma (mRCC) Meeting Abstract
| Authors: | Plimack, E. R.; Hammers, H. J.; Rini, B. I.; McDermott, D. F.; Redman, B. G.; Kuzel, T. M.; Harrison, M. R.; Vaishampayan, U. N.; Drabkin, H. A.; George, S.; Logan, T. F.; Margolin, K. A.; Xu, L. A.; Waxman, I. M.; Motzer, R. J. |
| Abstract Title: | Updated survival results from a randomized, dose-ranging phase II study of nivolumab (NIVO) in metastatic renal cell carcinoma (mRCC) |
| Meeting Title: | COSA's 42nd Annual Scientific Meeting |
| Journal Title: | Asia-Pacific Journal of Clinical Oncology |
| Volume: | 11 |
| Issue: | Suppl. 4 |
| Meeting Dates: | 2015 Nov 17-19 |
| Meeting Location: | Hobart, Australia |
| ISSN: | 1743-7555 |
| Publisher: | Wiley Blackwell |
| Date Published: | 2015-11-01 |
| Start Page: | 129 |
| Language: | English |
| ACCESSION: | WOS:000364320800188 |
| PROVIDER: | wos |
| PUBMED: | 26525766 |
| DOI: | 10.1111/ajco.12432_2 |
| Notes: | Meeting Abstract: 212 -- Source: Wos |
